Biopharma giants Eli Lilly and Regeneron and rapidly growing contract manufacturers Fujifilm and Cellares are among the seven ...
Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...
The FDA has issued a complete response letter to Unicycive over the “same third-party manufacturing deficiencies that were ...
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...
Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and ...
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to ...
As Amgen’s rare disease medicine Tavneos comes under intensifying pressure from the FDA, the company faces a new hurdle with ...
Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
In rejecting NASP, the FDA is delaying the launch of a gout drug that Sobi projected could reach up to 6 billion Swedish kroner ($620 million) in peak sales. (Photo by Sarah Silbiger/Getty Images) ...
The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results